Tarsus Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. The company also presented a webcast about this approval.